Difference between revisions of "Fluvoxamine-maprotiline"

From Psychiatrienet
Jump to: navigation, search
Line 12: Line 12:
 
* "Start low, go slow" is not required, but caution is necessary.
 
* "Start low, go slow" is not required, but caution is necessary.
 
* {{theorSS}}
 
* {{theorSS}}
 +
{{review}}
 
}}
 
}}

Revision as of 16:42, 21 October 2015

Fluvoxamine
Type Antidepressant
Group SSRI
links
Medscape Fluvoxamine
PubChem 5324346
PubMed Fluvoxamine
Kompas (Dutch) Fluvoxamine
Wikipedia Fluvoxamine
Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline

Switch medication from fluvoxamine to maprotiline.

Nietinrijdenbord.png Stop fluvoxamine
  • Before day 1: gradually reduce dosage of fluvoxamine to a maximum of 50 mg/ day when this dosage is > 50 mg/day.
  • Day 1: reduce dosage of fluvoxamine to a maximum of 25 mg/day.
Eenrichtingbord.png Start maprotiline
  • Day 1: simultaneously start administration of maprotiline in a low dosage of 25-75 mg/day.
  • Day 8: stop administration of fluvoxamine and continue administration of maprotiline. If necessary, increase dosage of maprotiline.
Infobord.png More information
  • Fluvoxamine slows the metabolism of maprotiline via CYP1A2 and CYP2D6.
  • "Start low, go slow" is not required, but caution is necessary.
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  • This switch is currently being reviewed.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.